Article thumbnail

Point-of-Care CD4 Testing to Inform Selection of Antiretroviral Medications in South African Antenatal Clinics: A Cost-Effectiveness Analysis

By Ciaranello Andrea L., Myer Landon, Kelly Kathleen, Christensen Sarah, Daskilewicz Kristen, Doherty Katie, Bekker Linda-Gail, Hou Taige, Wood Robin, Francke Jordan A., Wools-Kaloustian Kara, Freedberg Kenneth A. and Walensky Rochelle P.


Many prevention of mother-to-child HIV transmission (PMTCT) programs currently prioritize antiretroviral therapy (ART) for women with advanced HIV. Point-of-care (POC) CD4 assays may expedite the selection of three-drug ART instead of zidovudine, but are costlier than traditional laboratory assays.”): antenatal zidovudine (CD4 ≤350/μL) or ART (CD4>350/μL). Outcomes included MTCT risk at weaning (age 6 months), maternal and pediatric life expectancy (LE), maternal and pediatric lifetime healthcare costs (2013 USD), and cost-effectiveness ($/life-year saved). improved clinical outcomes and reduced healthcare costs., the higher initial cost of a one-time POC CD4 assay will be offset by cost-savings from prevention of pediatric HIV infection

Publisher: Public Library of Science
Year: 2015
DOI identifier: 10.1371/journal.pone.0117751
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.